IP Library Granted Patent US 10,144,727
Granted Patent B2
US 10,144,727 · App. 15/022,005 · Granted Dec 4, 2018

Deoxynojirimycin derivatives and methods of their using

Inventors: Urban Ramstedt (Bethesda, MD); Raju Penmasta (Herndon, VA); Hitesh Batra (Herndon, VA); Tam Nguyen (Gaithersburg, MD)
Assignee: Emergent Virology LLC
C07D405/06C07D211/40C07D211/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,144,727
App. No.
15/022,005
Granted
Dec 4, 2018
Kind
B2
Abstract

The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.

Claims (15)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a) a pharmaceutically effective amount of the compound according to claim 1 and b) a pharmaceutically acceptable carrier.

3. A method of treating a Dengue viral infection in a subject in need of such treatment comprising administering to the subject an effective amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the dengue viral infection is a Dengue 2 viral infection.

5. The method of claim 3 , wherein the subject is a mammal.

6. The method of claim 5 , wherein the subject is a human.

7. A method of treating an influenza viral infection in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the virus is an Influenza A virus.

9. The method of claim 8 , wherein the virus is a H3N2 subtype of the Influenza A virus.

10. The method of claim 8 , wherein the virus is a H1N1 subtype of the Influenza A virus.

11. The method of claim 7 , wherein the subject is a mammal.

12. The method of claim 11 , wherein the subject is a human being.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 29, 2026
From: OHA AGENCY LLC, IN ITS CAPACITY AS ADMINISTRATIVE AGENT
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 074509/0661 →
SECURITY INTEREST Recorded Apr 16, 2026
From: EMERGENT BIOSOLUTIONS INC.; EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT TRAVEL HEALTH INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 074389/0054 →
SECURITY INTEREST Recorded Sep 30, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS INC.; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT TRAVEL HEALTH INC.; EMERGENT BIOSOLUTIONS CANADA INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 068746/0698 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 3, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 068829/0873 →
NOTICE OF GRANT OF SECURITY INTEREST IN U.S. PATENTS Recorded Sep 3, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS CANADA INC.; EMERGENT BIOSOLUTIONS INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT TRAVEL HEALTH INC.
To: OHA AGENCY LLC
Reel/Frame 068828/0233 →
SECURITY INTEREST Recorded May 18, 2023
From: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 063690/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2020
From: EMERGENT VIROLOGY LLC
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 051626/0388 →
CHANGE OF NAME Recorded Aug 7, 2018
From: UNITHER VIROLOGY, LLC
To: EMERGENT VIROLOGY LLC
Reel/Frame 046730/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: RAMSTEDT, URBAN; PENMASTA, RAJU; BATRA, HITESH; NGUYEN, TAM
To: UNITHER VIROLOGY, LLC
Reel/Frame 046730/0827 →
Continuity (2)
Provisional Application 61878286 · Sep 16, 2013
Related Publication 20160221993A1 · Aug 4, 2016